Más Dermatol. 2022;38:11-13 doi:10.5538/1887-5181.2022.38.11 13 MI PACIENTE ES… Xantogranuloma juvenil con involución atrófica-anetodérmica García Morales I leading to a wide atrophic sequela. Pediatr Dermatol. 2004;21(2): 121-3. 3. Bergman R, Aviram M, Shermer A, Oiknine Y, Vardi DA, Friedman-Birnbaum R. Enhanced low-density lipoprotein degradation and cholesterol synthesis in monocyted-derived macrophages of patients with adult xanthogranulomatosis. J Invest Dermatol. 1993;101(6):880-2. 4. Hernández-Martín A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol. 1997;36(3 Pt 1):355-67; quiz 368-9. 5. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol. 1996;34(3):445-9. 6. Zvulonov A, Barak Y, Metzker A. Juvenile xanthogranuloma, neurofibromatosis and juvenile chronic myelogenous leukemia. World statistical analysis. Arch Dermatol. 1995;131(8):904-8. 7. Marrogi AJ, Dehner LP, Coffin CM, Wick MR. Benign cutaneous histiocytic tumors in childhood and adolescence, excluding Langerhans’ cell proliferations. A clinicophatologic and immunohistochemical analysis. Am J Dermatopathol. 1992;14(1): 8-18. 8. Mun JH, Ohn J, Kim KH. Dermoscopy of giant juvenile xanthogranuloma. J Am Acad Dermatol. 2017;76(2S1):S76-8. 9. Sannier K, Dompmartin A, Gallet B, Comoz F, Labbé D, Penven K, et al. Involution atrophique de xanthogranulomes juveniles. Ann Dermatol Venereol. 2003;130(11):1047-50.
RkJQdWJsaXNoZXIy MTAyMDQzMg==